Boston Scientific (BSX) Earnings Date & Reports
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts... Show more
BSX is expected to report earnings to rise 3.71% to 82 cents per share on July 29
Boston Scientific (BSX) Q1 2026 Earnings Recap: Revenue and EPS Beat Estimates
Key Takeaways
- Boston Scientific reported Q1 net sales of $5.203 billion, up 11.6% year-over-year on a reported basis and 9.4% organically, surpassing consensus estimates of $5.18 billion.
- Adjusted earnings per share (EPS) came in at $0.80, edging out the $0.79 consensus and prior guidance range of $0.78-$0.80.
- Cardiovascular segment sales grew 13.5% reported (11.2% organic), driving overall performance, while MedSurg rose 7.8% reported.
- Full-year 2026 guidance trimmed to 7.0-8.5% reported sales growth and adjusted EPS of $3.34-$3.41 amid headwinds.
- Shares rallied post-earnings, gaining over 6% in pre-market trading despite the outlook cut.
- Key pipeline wins include positive trial data for WATCHMAN FLX and FARAPULSE systems.
Earnings Context and Why It Matters
Boston Scientific, a leader in medical devices, continues to navigate a dynamic healthcare landscape marked by innovation demands and procedural volume recovery. This Q1 2026 report is pivotal as it reflects post-pandemic growth momentum in its Cardiovascular and MedSurg (Medical and Surgical) segments amid macroeconomic pressures like inflation and supply chain issues. Investors watch closely for execution on high-growth areas like electrophysiology and structural heart, which could solidify BSX's competitive edge against peers. Strong international expansion, particularly in APAC and LACA regions, underscores global diversification, making this earnings a key gauge of sustained profitability and pipeline progress in a $500 billion medtech market.
Boston Scientific delivered Q1 net sales of $5.203 billion, exceeding analyst expectations of approximately $5.18 billion and the company's guidance midpoint. Reported growth was 11.6%, with organic growth (excluding foreign exchange and acquisitions) at 9.4%, driven by robust Cardiovascular performance (13.5% reported growth) including structural heart and endoscopy. MedSurg sales increased 7.8% reported.
Adjusted EPS reached $0.80, topping the $0.79 consensus and year-ago $0.75, reflecting operational efficiencies despite rising expenses. GAAP EPS was $0.90, with net income attributable to common stockholders at $1.341 billion. Gross margin stood at 69.2%, while operating income rose to $1.101 billion.
Regionally, U.S. sales grew 10.9%, EMEA 10.1% reported (1.2% operational), APAC 14.7% reported, and LACA 19.0% reported. The company completed the acquisition of Valencia Technologies' eCoin system and highlighted clinical wins like the CHAMPION-AF trial for WATCHMAN FLX, confirming reduced bleeding risks versus anticoagulants.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across sectors like healthcare.
Market Reaction and Investor Sentiment
BSX shares jumped in pre-market trading following the release, rising over 6.5% to around $63.41, and continued gains into the session, up as much as 9% intraday. The positive reaction stemmed from the earnings and revenue beats, offsetting concerns over trimmed full-year guidance. Investors appeared to view the results as validation of core growth drivers in Cardiovascular, with analysts noting a potential "reset" for valuation amid conservative outlook.
Forward Outlook and Key Factors to Monitor
Boston Scientific's updated FY 2026 guidance calls for net sales growth of 7.0-8.5% reported (6.5-8.0% organic) and adjusted EPS of $3.34-$3.41, reflecting caution around supply chain disruptions, foreign exchange headwinds, and segment-specific challenges like endoscopy. Q2 guidance projects 5.5-7.5% reported sales growth and EPS of $0.82-$0.84.
Investors should track progress on the innovation pipeline, including launches of FARAPULSE pulsed field ablation (PFA) system following ADVENT trial success and expansions for WATCHMAN FLX in atrial fibrillation treatment. Regulatory approvals, such as China clearance for OPAL HDx with FARAPULSE, could boost APAC momentum.
Integration of recent acquisitions like eCoin for urinary incontinence and monitoring cost trends, including EU MDR (European Union Medical Device Regulation) expenses and amortization from deals, will be critical. Broader factors include procedural volumes, reimbursement dynamics, and competitive pressures in structural heart and neuromodulation. Geopolitical risks and manufacturing resilience remain key watches.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a maker of medical devices
Industry MedicalNursingServices